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Recruitment and activation of neutrophils at sites of infection/inflammation relies largely on the surface expression 
of G-protein coupled receptors (GPCRs) that recognize chemoattractants. One of these receptors, FPR1, for which 
formylated peptides generated by bacteria and mitochondria are high affinity agonists, was among the first human 
neutrophil GPCRs to be cloned. This receptor shares large sequence homologies with FPR2, another neutrophil 
member of the FPR-family, but with a distinct ligand binding profile. The two FPRs transduce very similar 
neutrophil responses but possess somewhat different regulatory profiles. The FPRs have served as excellent model 
receptors in studies attempting to understand not only GPCR related regulation in general, but also receptor 
signaling in relation to innate immune reactivity and inflammation. Recent research has identified not only a large 
number of conventional ligands (agonist/antagonists) that regulate FPR activities by binding to surface exposed parts 
of the receptors, but also a number of membrane penetrating molecules that allosterically modulate receptor function 
after passing the membrane and interacting with the receptor on the cytosolic side. After activation, FPR signaling 
is rapidly terminated and the receptors become desensitized, a dormant state that can be achieved by multiple 
mechanisms. A coupling of the activated receptors to the actin cytoskeleton in a process that physically separates the 
receptors from the signaling G-protein is one such mechanism. Traditionally, the desensitized state has been viewed 
as a point of no return, but recent findings challenge this view and demonstrate that desensitized FPRs may in fact 
be reactivated to resume active signaling. The FPRs have also the capacity to communicate with other receptors in a 
hierarchical manner and this receptor cross-talk can both dampen and amplify neutrophil responses. In this review, 
we summarize some recent advances in our understanding of how the FPRs can be turned on and off and discuss 
some future challenges, including mechanisms of allosteric modulation, receptor cross-talk, and FPR reactivation. 
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Neutrophil chemoattractant receptors - focusing on the 
formyl peptide receptors (FPRs) 
The chemoattractant receptors and neutrophil function 
Based on the fact that prokaryotes initiate protein 
synthesis with a formylated methionine (fMet) residue, it 
was anticipated almost 40 years ago that peptides starting 
with fMet should be recognized by the immune  
system, and cells equipped with proper recognition 
structures (receptors) should be able to find the peptide 
source through chemotactic migration[1]. In accordance 
with this, chemotactic fMet-containing peptides were also 
identified as pro-inflammatory mediators released by 
growing Escherichia coli[2]. Subsequently, the application 
of molecular biology techniques led to the identification 
and characterization of the formyl peptide receptor 
(FPR1)[3]. This was among the first neutrophil receptors 
belonging to the large family of G-protein coupled 
receptors (GPCRs) that was cloned, but soon after two 
additional FPR1-like receptors, now known as FPR2 
(previously FPRL1) and FPR3 (previously FPRL2), were 
cloned from a promyelocyte cDNA library using low-
stringency hybridization with the FPR1 cDNA as a probe[4, 
5]. The last decade’s research has highlighted a role of the 
FPRs not only in host defence against bacterial infections, 
but also in immune regulation[5]. The three FPRs (FPR1, 
FPR2, and FPR3) belong to the subfamily of 
chemoattractant GPCRs that also includes, e.g., receptors 
for the complement component C5a (C5aR), the lipid 
metabolite platelet activating factor (PAFR) and the 
chemokine IL-8 (CXCR1/2)[6]. These chemoattractant 
receptors have in common that they comprise a single 350-
370 amino acids long polypeptide chain that spans the cell 
membrane seven times. The amino terminus and three 
extracellular loops (facing the cell exterior) are believed to 
be essential for interaction with the chemoattractant, while 
the carboxyl terminus and the three intracellular loops 
(facing the cytosolic side of the membrane) are of 
importance for signaling[6-8]. The transmembrane regions 
as well as the cytosolic signaling domains of the 
chemoattractant GPCRs share certain sequence similarities 
whereas the degree of sequence similarity is less obvious in 
the extracellular domains supposed to contain agonist 
recognition sites[9]. Receptor recognition of a 
chemoattractant in neutrophils typically induces not only 
chemotactic migration, but also exocytosis leading to 
mobilization of receptors and adhesion molecules from 
intracellular storage granules, secretion of proteolytic 
enzymes and inflammatory mediators, and production of 
reactive oxygen species (ROS) by the activated NADPH-
oxidase[10].  
The human FPRs 
It was for many years believed that the 
expression/distribution of FPRs was restricted to 
phagocytes, a view that has been reconsidered and we now 
know that these receptors are expressed also in a variety of 
non-immune cell types[11]. Regarding the expression in 
professional phagocytes, human neutrophils express FPR1 
and FPR2 whereas monocytes/macro-phages express all 
three family members[5]. FPR1 and FPR2 exhibit an amino 
acid sequence similarity of 69% with a higher degree of 
identity in the cytosolic loops and a lower in the 
extracellular domains and carboxyl tail[5] (Fig 1). This 
suggests that the two receptors differ more with regards to 
ligand binding than in what type of intracellular signals 
they transmit. Further, FPR1 displays a high degree of 
single nucleotide polymorphism, whereas no 
polymorphisms have been described for FPR2[12]. This 
indicates that although these receptors are quite similar, 
they have been subjected to distinctly different 
evolutionary events. The two neutrophil FPRs are 
expressed fairly late during neutrophil differentiation (after 
the promyelocyte stage)[13], they mediate very similar 
cellular responses[14], and have the same subcellular 
distribution in mature neutrophils, i.e., the major part is 
stored in easily mobilizable granules/secretory vesicles, as 
reviewed by subcellular fractionation studies[15, 16]. The 
stored FPRs can be mobilized to the cell surface by priming 
agents such as bacterial endotoxin and TNF-, but they also 
become surface-exposed during the process of 
extravasation from the blood stream to the tissue[15, 17, 18].  
The murine Fprs 
The FPR gene cluster has undergone differential 
expansion in mammals[19]. The murine genome comprises 
eight distinct Fprs (rather than three as in humans) with 
unique functional and distribution characteristics [19-21]. It is 
also worth mentioning that the prototypic FPR1 agonist 
fMLF is a much less potent stimulus of murine 
neutrophils[22-24]. The evolutionary relationship and 
functional correlation between human FPRs and their 
mouse counterparts remain incompletely understood, but 
the available data suggest that the murine Fpr1 is an 
ortholog of human FPR1 but with much lower affinity for 
formyl peptides[21, 25]. The observation that the WKYMVm 
peptide, a potent FPR1/2 dual agonist[26], activates 
transfected cells expressing murine Fpr-rs2, suggests that 
this receptor may be the mouse ortholog of FPR2, but cross 
desensitization experiments indicate that also other murine 
receptors may recognize this agonist[27]. Despite the 
insufficient knowledge about the murine Fprs in general, it 
is however evident that activation of these receptors 
induces similar cellular responses as their human 
counterparts [22, 23, 28-30]. An additional similarity is that 
exudate murine neutrophils are primed in their response to 
WKYMVm and this FPR1/2 dual agonist desensitizes the 
murine cells for subsequent stimulation with several FPR1 
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agonists as well as the specific FPR2 agonist WKYMVM[31, 
32]. The priming process of murine neutrophils involves 
mobilization of subcellular granules, suggesting that the 
subcellular localization profiles for the receptors in human 
and murine neutrophils are similar[27].  
Ligand specificity and selectivity for FPR1 and FPR2 
Conventional FPR agonists  
FPR1 is a high affinity receptor involved in guiding 
neutrophils to bacteria or damaged tissue through 
recognition of formyl peptides[1, 33]. In addition to formyl 
peptides, a number of different FPR1 agonists have been 
identified including non-formylated host-derived peptides, 
as well as non-peptide agonists identified from library 
screens. The reader is referred to other recent reviews for a 
full description of FPR specific/selective ligands[10, 11]. 
When comparing FPR1 and FPR2, it is clear that the latter 
displays a much more diverse ligand profile and this 
receptor recognizes a broad range of molecules including 
the GP-41 envelope protein of the human 
immunodeficiency virus type 1 (HIV-1)[34], a peptide from 
glycoprotein G of herpes simplex virus type 2[35], Hp2-20 
from Helicobacter pylori[36], and the synthetic peptide 
WKYMVM/m[18]. Also host-derived molecules have been 
suggested to be FPR2 ligands, most notably the acute phase 
protein serum amyloid A (SAA) [37]. However, most (if not 
all) studies on the SAA-FPR2 link have been performed 
with a recombinant protein that is a hybrid of two human 
SAA isoforms (SAA1 and 2) that does not exist in vivo. It 
is thus highly debatable if the notion that acute phase SAA 
is a cytokine-like protein with pro-inflammatory properties, 
really reflect the true biological activity of endogenous 
SAA. We recently showed that the native protein, obtained 
from patients with inflammatory arthritis, is remarkably 
inert and do not share the neutrophil activating properties 
Figure 1. Schematic drawing of FPR. The amino acid sequences for FPR1 (350 
amino acids) and FPR2 (351 amino acids) are very similar and the majority of 
differences are located in the extracellular domains. Grey circles denote amino acids 
that are identical between FPR1 and FPR2, red circles represent residues that are 
different between FPR1 and FPR2. The third intracellular loop is framed in green and 
the sequences are specified below. This sequence (FPR2) is the basis for activating 
FPR2 pepducins as described in the text. 
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of recombinant SAA[38, 39]. Thus, the recombinant forms of 
SAA are not valid substitutes for the native protein, but 
since they are indeed capable of interacting with FPR2[39, 
40], they may still be of value for studying receptor biology.  
Another host-derived molecule that interacts with the 
FPRs is annexin I, a member of the annexin family of 
calcium-regulated phospholipid binding proteins involved 
in regulation of innate and adaptive immunity [41]. Peptides 
derived from the N-terminus of annexin I have both pro- 
and anti-inflammatory activities[29, 42-44]. All three FPRs 
recognize different and possibly overlapping parts of the 
protein with a core structure for FPR1 interaction identified 
as Gln(9)-Ala(10)-Trp(11)-Phe(12) corresponding to the 
annexin I9-12 sequence[45]. A structural model of this peptide 
agonist-FPR1 complex suggests that the transmembrane 
part of the binding pocket of the receptor binds optimally 
to this tetrapeptide[45]. According to the model, the N-
terminal glutamine of the peptide is located close to the 
bottom of the binding cleft, leaving for steric reasons 
insufficient space to extend the peptide at the N-terminus, 
information that may be helpful for the development of 
specific FPR1 ligands[45].  
Although several peptide/protein agonists for the FPRs 
have been identified, more stable and selective small-
molecule ligands should be valuable tools for a better 
understanding of the physiologic roles played by these 
receptors. When it comes to the identification non-
peptide/protein agonists for FPRs, high throughput 
screening of small compound libraries in cells over-
expressing FPR1 or FPR2 has been the system of choice for 
rapid data acquisition and ligand identification. Several 
high-affinity agonists (and some antagonist/inhibitors) 
have been identified and characterized through such 
screening approaches[46-48], and some potent agonists 
originally identified with FPR2-expressing cells have later 
been demonstrated to interact preferentially with FPR1[48, 
49]. The small-molecules identified as FPR agonists using 
transfected cells were shown to activate also the neutrophil 
receptors and comparative docking studies show that 
agonists with dual specificity (FPR1/FPR2) bind to similar 
binding pockets as high affinity FPR1 and FPR2 peptide 
agonists, respectively[50, 51]. Many of the identified small-
molecule compounds could possibly be used as potential 
lead compounds for further development of highly potent 
and selective FPR agonists/antagonists.    
Peptides starting with an N-formyl methionyl group 
constitute a unique pattern of bacterial as well as 
mitochondrial metabolism[33], but since FPR2 hardly 
recognizes the prototypic bacterial chemoattractant fMLF, 
FPR1 was for a long time regarded as the sole receptor 
capable of recognizing formyl peptides. However, this 
notion has been challenged by the recent finding that 
community-associated methicillin resistant Staphylococcus 
aureus (CA-MRSA) secrete a group of FPR2 binding 
Figure 2. FPR-mediated neutrophil activation upon stimulation with a conventional agonist (left) that binds to the 
extracellular receptor domains, or by a pepducin (right) that anchors to the membrane through its palmitoyl moiety 
(black) and interacts with the receptor at the signaling interface on the cytoplasmic side. Both agonists trigger G-
protein-dependent signaling and induce very similar cellular responses.  
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peptides, the so called phenol soluble modulins (PSMs)[52, 
53]. These PSM peptides are secreted by the recently 
identified PSM transporter from the bacteria without 
removal of the formyl group at the N-terminal methionine 
(deformylation) and they all have in common that they are 
α-helical molecules with a high degree of amphipathicity[54]. 
All PSMα peptides (grouped by their size, physicochemical 
properties and genomic arrangement) investigated promote 
virulence through effects on discrete neutrophil functions 
(i.e., chemotaxis) and by being cytotoxic at higher 
concentrations[55-57]. The physicochemical properties of 
their C-terminus are crucial not only for the cytotoxic 
activity but also for the receptor activation potency of the 
peptide. Regardless of the C-terminal sequence these 
formyl peptides always seem to prefer FPR2 over FPR1[52]. 
This suggests that the name FPR2 is fitting not only based 
on the close structural similarity with FPR1, but also based 
on the ability to recognize fMet-containing peptides.  
FPR antagonists and non-conventional FPR agonists  
Several ligands have been described that interact with 
FPR and inhibit the cellular responses more or less 
specifically[58, 59]. Antagonism of GPCRs can be achieved 
through different mechanisms, e.g., by binding of an 
inhibitor to a receptor site different from that used by 
conventional agonists (allosteric inhibition), or by binding 
of an inhibitor to the same receptor site as conventional 
agonists (orthosteric inhibition)[60]. The latter type of 
inhibitors could exert their effect either by competitive 
binding (a neutral antagonist), or by being an inverse 
agonist that inhibits the basal activity of a constitutively 
active receptor. The FPR1 selective inhibitor cyclosporin H, 
a cyclic undecapeptide, has been shown to be an inverse 
agonist[61, 62]. No precise inhibitory mechanisms have been 
defined for the identified FPR2 inhibitors (described below) 
and whether also FPR2 is constitutively active in the 
absence of agonist is not known.     
Despite the fact that cyclosporin H is the most potent and 
selective FPR1 inhibitor described, several other more or 
less specific FPR1 inhibitors have been identified. 
Replacement of the formyl group in the prototype agonist 
fMLF with a bulky t-butyloxylcarbonyl (Boc)- or 
isopropylureido-groups yields FPR1 antagon-ists, and the 
potency of such antagonists can be changed through a 
replacement of the individual amino acids in the peptide[58]. 
Moreover, the anionic amphiphil sodium dodecyl sulfate 
(SDS) was recently shown to act as an FPR1 antagonist 
with fairly high receptor specificity; signaling through 
FPR2 was actually slightly primed by SDS[63]. The precise 
mechanism behind this is not known, but might be related 
to effects earlier described for SDS on the small G-protein 
Rac, that is of importance for a proper transduction of the 
down-stream signals from the occupied receptor[64]. With 
respect to the antagonistic effect of SDS, both the length of 
carbohydrate chain and the net charge of the molecule are 
of importance[63].  
A recent search for new FPR antagonists, using a ligand-
based virtual screening approach, identified 30 different 
FPR antagonistic compounds belonging to 9 distinct 
chemical families[65], suggesting that there will be an 
increasing number of antagonists identified also for FPR2. 
The FPR2-specific antagonists/inhibitors described so far 
are the recently identified hexapeptide WRWWWW[66] and 
the cell permeable allosteric modulator PBP10 ([67], 
described below). Both WRWWWW and PBP10 block 
FPR2-mediated responses without affecting FPR1 
signaling [66-69]. However, these antagonists/inhibitors are 
Figure 3. Schematic drawing of FPR activation (left), desensitization (middle), and reactivation (right). The FPRs (both 
FPR1 and FPR2), subsequent to agonist binding, rapidly undergo homologous desensitization by coupling to the actin 
cytoskeleton. FPR agonist induce also heterologous desensitization of e.g., CXCR1/2, no superoxide is induced by a second 
stimulation CXCR1/2 agonist. The desensitized FPRs can be reactivated by either disruption of the actin cytoskeleton, or by 
cross-talk signals triggered through PAFR or the ATP receptor P2Y2. Reactivated FPRs transmit signals that activate 
neutrophils to produce superoxide, but no Ca2+ transients are induced by reactivation. 
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not entirely FPR2-specific since both inhibit also FPR3 
signaling (our unpublished observations).  
Among the more mysterious inhibitors for the FPRs are 
the endogenous lipid mediators, lipoxins and resolvins. The 
formation and activity of lipoxins and resolvins have been 
shown to be of prime importance for the resolution of 
inflammation in a great number of murine models and this 
inhibitory approach is currently being developed for anti-
inflammatory therapies[70, 71]. The lipoxygenase-derived 
eicosanoid lipoxin A4 (LXA4) was the first specific agonist 
shown to bind to FPR2 with high affinity[72], and resolvin 
D1 (belonging to a group of non-classical eicosanoids) has 
recently been shown to trigger the same receptor[73]. In 
contrast to the large number of non-lipid FPR2 agonists 
identified in recent years, the lipids have been suggested to 
use some of the signaling pathways commonly used by 
classical agonists, but at the same time inhibit neutrophil 
functions[74]. Based on these observations the 
lipoxins/resolvins should be classified as biased agonists, 
but it should be noticed that several studies clearly show 
that LXA4 neither inhibits neutrophil functions, nor triggers 
the signaling pathways commonly used by classical 
agonists[32, 75-77]. These results imply that the anti-
inflammatory actions of LXA4 may be FPR2-independent.  
Intracellular allosteric modulation of the FPRs 
Intracellular allosteric activation by FPR-derived 
pepducins  
The development of a group of lipidated peptides 
(pepducins) has recently introduced a new concept for the 
regulation of GPCR activity[78]. Members of this group of 
GPCR regulators affect receptor function through unique 
allosteric mechanisms that basically involve cytosolic parts 
of sensitive receptors, and not the receptor domains 
typically used by conventional agonists that bind to the 
extracellular loops of the receptors and possibly also to the 
transmembrane regions localized close to the cell 
surface[78-80]. In contrast to conventional agonists, the 
activity of pepducins depends on their capability to pass 
through membranes and affect receptor activities from the 
cytosolic side of the membrane[81] (Fig 2). A pepducin 
typically comprises a fatty acid (normally palmitic acid) 
linked to a short peptide chain with an amino acid sequence 
identical (or very similar) to one of the intracellular loops 
or the cytoplasmic tail of the targeted GPCR. The N-
terminally linked palmitoyl group acts as a hydrophobic 
anchor and is of prime importance for the ability of the 
pepducin molecule to pass the membrane and allow the 
peptide to target the receptor from the cell interior[79]. It 
should be noticed that pepducins may either activate or 
inhibit receptor function and the signals that are generated 
are very similar to those induced by conventional 
activating/inverse agonists[82]. Pepducins with amino acid 
sequences originating from the third intracellular loop of 
FPR2 have the capacity to activate neutrophils through an 
interaction with this receptor[82, 83] (Fig 2). Although FPR1 
and FPR2 are very similar at the amino acid level, 
particularly in the third intracellular loop of the receptors 
(Fig 1), the corresponding FPR1-like pepducin is not able 
to activate this receptor[82], showing that there are indeed 
clear differences in signaling between these very closely 
related receptors.  
Although it is hard to understand why/how pepducins 
with amino acid sequences identical to a cytosolic part of a 
GPCR specifically interact with the receptor from which it 
is derived, it is clear that an FPR2-specific pepducin solely 
activates cells that express FPR2[82]. The precise 
mechanism by which pepducins transduce signals in a 
receptor specific manner require further studies, but 
different, and possibly unique, modes of action may be 
utilized depending on the particular experimental set up and 
the individual pepducin/receptor pair examined. As of yet, 
no inhibitory pepducins, based on sequences from FPRs 
linked to a palmitoyl group has been described. 
Intracellular allosteric inhibition by gelsolin-derived PIP2-
binding peptides  
Another allosteric modulator, distinct from the 
pepducins, is the FPR2-selective inhibitor PBP10 that 
contains a peptide sequence identical to one of the PIP2-
binding domains of the cytoskeletal protein gelsolin[69, 84]. 
The PBP10 peptide has a rhodamine group conjugated to 
its N-terminus, and this is apparently required for the 
peptide to pass the plasma membrane[85], and for the 
inhibitory function of the peptide[67]. A core PBP peptide 
for FPR2 inhibition has been identified, and the fact that 
this shorter peptide partly inhibits also FPR1[69], suggests 
that a structure of importance for inhibition is present also 
in FPR1 but this is obviously not accessible for the longer 
peptide.  
It is hard to conclusively show that the allosteric 
modulators described interact with its specific receptor 
from the inside of the plasma membrane, but it is clear that 
PBP10 as well as the FPR2-derived pepducins indeed have 
the capacity to pass the plasma membrane and that the 
physicochemical properties (charge and hydrophobicity) 
that permit them to enter the cytoplasm are also required 
for proper function. In accordance with this, the naked 
peptides are completely devoid of biological activity[82, 85]. 
FPR desensitization and reactivation  
Homologous and heterologous desensitization  
As reviewed elsewhere, agonist-induced activation of 
FPRs is regulated at multiple levels; receptor to G-protein 
activation, transduction and amplification of signals from 
activated G-proteins to effectors including kinases and 
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small GTPases, and integration of effector signals leading 
to phagocyte responses such as chemotaxis, degranulation, 
and superoxide generation[10, 11]. One particularly important 
regulatory process is receptor desensitization, a process 
whereby GPCRs lose the ability to signal and this is thus a 
mechanism whereby prolonged activation can be avoided. 
Homologous desensitization is a process by which 
neutrophils interacting with a receptor-specific agonist 
gradually become non-responsive to further stimulation by 
the same agonist as well as to other agonists employing the 
same receptor[86]. Activation of e.g., FPR1 will lead to 
desensitization and unresponsiveness to subsequent 
stimulation with FPR1 agonists[18]. However, agonist 
binding to FPRs triggers also the desensitization of other 
unrelated receptors including CXCR1/2 (Fig 3). This type 
of receptor cross-talk is known as heterologous 
desensitization[87]. Heterologous desensitization occurs in a 
hierarchical manner and may be of importance for 
directional migration to the focus of infection and/or 
inflammation when cells are facing multiple gradients of 
different chemoattractants[88]. Interestingly, no cross 
desensitization is observed with specific FPR1 and FPR2 
agonists, which suggest that these two receptors are 
hierarchically equally strong[18]. The desensitization 
phenomenon can be used to characterize new receptor 
agonists and to determine receptor hierarchy but it is of 
importance to notice that desensitization patterns may 
differ depending on the read-out system. The background 
to this is that certain agonists (e.g., fMLF) may be 
inactivated by a myeloperoxidase/hydrogen peroxide 
catalyzed reaction and by that the desensitization is 
broken[89]. Several approaches can, however, be used to 
avoid the influence of agonist inactivation[90]. 
Many desensitization mechanisms have been proposed 
including the phosphorylation of occupied GPCRs by 
specific GPCR kinases, second messenger-dependent 
protein kinases, β-arrestin binding, and physical coupling 
of the receptor to the cytoskeleton[9, 91]. It is clear that the 
actin cytoskeleton beneath the neutrophil cell membrane 
(also known as the cortical cytoskeleton) plays an 
important role at least in homologous desensitization of 
FPRs. As an example, a disruption of the actin cytoskeleton 
with cytochalasin B or latrunculin A prolongs the FPR 
signaling without affecting signaling stemming from 
GPCR-independent activation, e.g., by PMA (a direct PKC 
activator)[92]. Similar to cytoskeletal disrupting agents, the 
inhibition of cellular phosphatases by treatment with 
okadaic acid or calyculin A also delays termination of FPR 
signaling, an effect that is accompanied with reduced 
association of the receptor-ligand complex to the actin 
cytoskeleton[93]. Jesaitis et al. have demonstrated that upon 
formyl peptide binding to FPR1, the formation of Triton X-
100 resistant FPR1-cytoskeleton complexes occurs before 
receptor internalization [94]. The basis for cytoskeleton-
dependent GPCR desensitization is thus proposed to 
involve a physical segregation of the receptor from the 
signaling G-protein and coupling to the actin cytoskeleton 
[91] (Fig 3). The precise mechanism for how activated FPRs 
display binding affinity for the actin cytoskeleton and how 
this association separates the receptor from the signaling G-
protein is not yet understood. The fact that the cytoplasmic 
signaling/phosphorylation regions of FPR1 shares 40-50% 
identity with actin-binding proteins such as villin suggests 
that FPRs may directly bind to the actin cytoskeleton[95].  
FPR reactivation involving the actin cytoskeleton 
A key role of the actin cytoskeleton in FPR 
desensitization gains further support from the fact that 
desensitized neutrophils can be reactivated to produce 
superoxide by the secondary addition of a cytoskeleton-
disrupting agents[67, 96]. When the agonist-bound FPRs have 
terminated signaling, these receptors are homologously 
desensitized and do not respond to subsequent doses of the 
same agonists. This desensitized state had for a long time 
been considered a stable point of no return, i.e., that it 
would not be possible to transfer the desensitized receptors 
back into signaling mode again. However, by addition of 
pharmacological agents that disrupt the cytoskeleton 
(cytochalasin B or latrunculin A) to FPR-desensitized cells, 
these receptors rapidly resume signaling again, a process 
termed receptor reactivation [96] (Fig 3). The actin-
dependent desensitization mechanism is not universal for 
all GPCRs as evidenced by the fact that cells desensitized 
by IL-8 (CXCR1/2) or PAF (PAFR) cannot be reactivated 
to produce superoxide anion by cytochalasin B or 
latrunculin A[97].  
Whereas pharmacological disruption of the cytoskeleton 
may be a rather artificial way to achieve reactivation of 
desensitized FPRs, we have recently found that a similar 
process can be triggered by stimulation of PAFR or the 
ATP receptor P2Y2 that transmits cross-talking signals to 
the desensitized FPRs ([98, 99] and described below). This 
indicates that FPR reactivation could actually take place 
and be of importance during physiological settings. Taken 
together, this clearly indicates that the block, e.g., actin 
cytoskeleton, put on desensitized FPRs and that refrain 
them from transmitting their signals is not permanent, but 
can in fact be removed.  
FPR reactivation induced by receptor cross-talk  
Recent research has demonstrated that receptor cross-
talk can not only induce desensitization, but as mentioned 
above it can also trigger reactivation of desensitized FPRs 
when FPR-desensitized neutrophils are stimulated with 
ATP (that bindisto the ATP receptor P2Y2[99]), or with PAF 
(that binds PAFR expressed in the plasma membrane)[98, 100] 
(Fig 3). This shows that stimulation of unrelated GPCRs 
(e.g., PAFR) generates signals that are capable of lifting the 
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block put on desensitized FPRs and turn the dormant 
receptor-ligand complex back into signaling mode again. 
Interestingly, this PAFR-mediated reactivation of FPRs 
takes place even if the cytoskeleton has been disrupted prior 
to PAF stimulation, suggesting the existence of non-actin 
mediated reactivation mechanisms. Also, the cross-talk 
between PAFR or P2Y2 and FPRs is unidirectional, i.e., 
FPR ligation cannot reactivate desensitized PAFR or 
P2Y2[98, 99]. The mechanistic details of the reactivation 
signal are still obscure, but whereas both neutrophil FPRs 
(FPR1 and FPR2) are susceptible to reactivation, other 
GPCRs, e.g., CXCR1/2 cannot be reactivated[97, 98], 
indicating that there is some kind of specificity involved in 
FPR cross-talk with other GPCRs.  
Signaling through neutrophil FPRs 
Common signaling pathways trigger a transient rise in 
intracellular Ca2+  
The signaling pathways downstream FPR1 have been 
extensively studied, and details about the signal 
transduction pathways for the onset of discrete neutrophil 
functions can be found in several recent reviews[9, 95, 101, 102]. 
Once activated, the dissociated G-protein subunits activate 
multiple downstream second messengers including various 
phospholipases and protein kinases[9, 103]. In contrast, less 
is known about FPR2 signaling, but it is generally assumed 
that they use very similar signaling pathways based on the 
fact that the two receptors are structurally very similar in 
their signaling domains and they also mediate very similar 
cellular responses[14]. Both FPRs, upon binding by a large 
array of ligands, adopt a conformational change that 
induces a dissociation of pertussis toxin-sensitive G-
proteins into two parts, the α and βγ subunits[104], and based 
on results obtained using a simple and straightforward 
system to measure β-arrestin binding, it is clear that both 
FPR1 and FPR2 trigger a translocation of β-arrestin[32].  
In resting neutrophils, the cytosolic Ca2+ concentration 
is kept at very low levels (about 100 nM) as compared to 
the level outside of the cells, and in a general signaling 
transduction scheme an immediate downstream 
consequence of GPCR activation is the transient elevation 
of intracellular Ca2+. The Ca2+-response triggered by FPR1 
agonists is characterized by an initial release of Ca2+ from 
intracellular storage organelles exposing IP3 receptors[105]. 
The emptying of the storage organelles then leads to the 
entry of extracellular Ca2+ through store-operated calcium 
channels in the plasma membrane, thereby prolonging the 
increase in intracellular Ca2+. A fundamental difference 
between the signaling profiles of FPR1 and FPR2 was 
recently described when FPR2 was shown to trigger a 
unique type of Ca2+ influx across the plasma membrane and 
it was without involvement of the intracellular storage 
organelles[106]. Thus, the influx of Ca2+ across the plasma 
membrane was not preceded by Ca2+ release from the 
intracellular stores. We have found that all specific FPR2 
agonists tested induce an increase in intracellular Ca2+ that 
also rely on a release from intracellular stores, clearly 
showing that Ca2+ signaling mediated via FPR2 in fact 
follows the same route as that of FPR1[107].  
The transient rise in intracellular Ca2+ is not required for 
neutrophil activation 
The temporary rise in Ca2+ described above has long 
been considered essential for various neutrophil functions. 
There are, however, studies showing that an elevation of 
Ca2+ alone is neither sufficient nor required for certain 
FPR-mediated neutrophil responses. It is clear that 
although many cytoskeleton-remodeling proteins require 
Ca2+ for proper function[108], cytoskeleton dependent 
cellular processes such as neutrophil polarization, 
membrane ruffling, chemotaxis and phagocytosis can take 
place also in Ca2+ depleted cells[109]. Also activation of the 
superoxide generating system can occur without an 
elevation of cytosolic Ca2+ and superoxide produced as a 
result of FPR reactivation occurs without any transient Ca2+ 
rise[87, 96, 97] (Fig 3). The experimental evidence suggesting 
that Ca2+ elevations activate downstream effector functions 
(i.e. granule mobilization and activation of the NADPH-
oxidase), directly or in synergy with other signals[110, 111], 
relies on methods that cannot distinguish a dependence of 
basal Ca2+ levels from a requirement for a Ca2+ transient. 
Our data showing that neutrophils can be activated without 
any cytosolic Ca2+ transients are thus in contradiction with 
the prevailing view.  
Future Perspectives 
The last decade’s research, with advanced cellular and 
molecular biology technologies, has generated an 
impressive amount of knowledge to increase our 
understanding of the members of FPR family. The recent 
progress in using allosteric modulators (activating as well 
as inhibitory) that interact with the FPRs from inside the 
plasma membrane is wildly different from the conventional 
scenario where GPCRs can only be targeted from the 
outside. This progress and the fact that desensitized FPRs 
can be reactivated to resume signaling add an additional 
layer of complexity to the classical view of FPR activation. 
Especially the finding that reactivation of desensitized 
FPRs can be achieved through GPCR cross-talk could have 
bearing on how neutrophils react to multiple gradients of 
different chemoattractants and the detailed nature of the 
cross-talk signal, and whether this mechanism applies also 
to other GPCRs (and other cell types) awaits further 
investigation. Most of the FPR agonists/antagonists 
described are related to infections or inflammatory 
processes, indicating that this group of GPCRs plays 
critical roles in host defense as well as for immune 
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regulation. This notion gains further support from in vivo 
studies using mice deficient in individual receptor subtypes 
showing that these mice display dysregulated inflammatory 
responses. However, when translating data from murine 
models into a human setting, it is important to be aware that 
many potent human FPR agonists/antagonists display very 
low affinity (or are even inactive) for the murine Fprs. 
Finally, the GPCR research has entered a new era due to 
the recent explosion in available GPCR crystal structures. 
Once proper structures of the FPRs have been resolved, 
these structures should open up new opportunities to study 
their function and offer conformational insights into FPR 
activation by conventional ligands as well as allosteric 
modulators. Hopefully, such knowledge would facilitate 
the elucidation of mechanisms underlying FPR 
desensitization and reactivation. Understanding of how 
FPR activity is regulated is of direct importance in 
physiological as well as pathological settings. Increased 
knowledge in these matters should facilitate the 
development of novel prophylactic and/or treatment 
strategies for autoimmune and inflammatory diseases. 
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